SCHEMBL1127319

SCHEMBL1127319

CCC(C)OC(=O)C(C(=O)O)C(=O)C(Cc1ccccc1)c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 1/20 0.36
PGR P06401 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35
PKM P14618 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
CPA1 P15085 1/20 0.35
CYP2C19 P33261 1/20 0.35
PSMB5 P28074 1/20 0.35
P4HTM Q9NXG6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127394 0.93 MME (0.39) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127320 0.92 TSHR (0.44) MAPTMEN1GAAKMT2AALDH1A1
SCHEMBL1129447 0.91 ALDH1A1 (0.39) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127442 0.90 KDM4E (0.37) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127497 0.90 ALDH1A1 (0.36) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127832 0.89 TAAR1 (0.40) KMT2AALDH1A1TSHRKDM4ECPA1
SCHEMBL4281414 0.88 MME (0.38) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127310 0.87 KMT2A (0.36) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL1127255 0.86 ALDH1A1 (0.43) MAPTSMN1; SMN2MEN1GAAKMT2A
SCHEMBL4278338 0.85 MEN1 (0.40) MAPTSMN1; SMN2MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MAPT 4342/4885SMN1; SMN2 3563/4885MEN1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.